Amundi 13F: Adds $67M to CME Stake
Amundi has increased its stake in CME Group Inc. to over 2 million shares, reflecting a 13.7% rise in its position.
Reviewed by automated data checks against the source filing. How we make and check alerts
Amundi added 250,780 shares to its stake in CME Group Inc. ($CME), a 13.75% increase, according to a 13F filing with the SEC dated May 18, 2026. It reported 2,075,107 shares worth $552.14 million at the end of the quarter.
Since the filing, $CME is down 7.4% after 1 week, down 16.8% after 1 month and down 2.7% to date (from the $302.13 close on May 18, 2026).
CME
CME Group Inc.
Key Points
- Amundi boosted its position in CME Group Inc. (CME) by 250,780 shares, now holding a total of 2,075,107 shares valued at approximately $552.1 million as of May 18, 2026.
- CME Group's shares recently traded at $266.08, slightly below its 50-day moving average of $266.98 and well above its 52-week low of $218.31.
- Analysts maintain a consensus rating of 'Hold' for CME Group, with a mean price target of $283.60 based on 15 analyst opinions.
Get $CME trade alerts by text
We text you when insiders, Congress or big funds trade $CME. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated CME Group Inc. alert may contain errors. Disclosures
Amundi's Increased Stake in CME Group
Amundi has boosted its position in CME Group Inc. (CME) by 250,780 shares, raising its total holdings to 2,075,107 shares. This increase represents a 13.7% change in its position, with a reported value of about $552.1 million as of May 18, 2026. The filing reflects holdings as of the reporting period and may not represent the investor's current position.
Other Institutional Moves
Montrusco Bolton Investments recently initiated a new position in CME Group, acquiring 289,492 shares valued at approximately $75.8 million. This move adds to the growing interest in CME Group among institutional investors.
CME Group Stock Performance
CME Group's shares are currently trading at $266.08, just below its 50-day moving average of $266.98. The stock is also well above its 52-week low of $218.31, suggesting it has maintained a relatively strong position despite market fluctuations.
Recent Earnings
In its most recent earnings report, CME Group posted revenue of approximately $6.76 billion, reflecting a growth rate of 0.8%. The company reported an EPS of $11.79 and a net margin of 63.4%. The next earnings announcement is set for October 21, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target cuts vs 0 raises.
-
EPS & revenue
EPS missed estimates by 1.2%. Revenue missed estimates by 1.6%.
-
Profit surprise
EBITDA missed by 6 percent. Operating income missed by 5 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
2 target cuts.
-
Earnings quality
Gross margin up 0.7 points. Operating margin up 2.2 points. Positive free cash flow.
Earnings Call Summary
CME delivered a record first quarter with average daily volume of 36.2 million contracts, up 22 percent year-over-year, marking the highest in company history. Revenue reached $1.88 billion, up 14 percent, with record performance across all six asset classes and international markets. The company achieved record adjusted operating margins of 72.8 percent and adjusted earnings per share of $3.36, returning $3.2 billion to shareholders through dividends and buybacks.
Guidance CME reaffirmed its full-year adjusted expense guidance of about $1.695 billion. The company expects to continue investing in technology and cloud migration while maintaining capital returns through dividends and share buybacks.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Insider Buying and Selling at CME Group Inc.
On June 25, 2026, several insiders at CME Group made purchases, including Timothy Bitsberger, who bought 645 shares for $145,125, and Daniel Kaye, who also acquired 645 shares for the same amount. Other insiders, including Ford Harold Eugene JR., Tierney Robert JR., and Patrick Maloney, also made similar purchases, indicating a positive outlook from the company's leadership.
Analysts Set New Price Targets
Wells Fargo and Morgan Stanley both maintain an 'Overweight' rating on CME Group, with price targets of $315 and $337, respectively. Barclays has an 'Equal-Weight' rating with a target of $281, while UBS rates it as 'Neutral' with a target of $270. The overall consensus remains a 'Hold' with a mean price target of $283.60 based on 15 analyst opinions.
What CME Group Inc. Does
CME Group Inc., based in Chicago, operates markets for trading futures and options on various assets, including interest rates, equity indexes, and commodities. The recent boost in holdings by Amundi and other institutions reflects confidence in CME Group's ongoing performance and market position.
What’s Next for CME Group
Investors will be watching for CME Group's next earnings report on October 21, 2026, as well as any further changes in institutional holdings. The latest 13F filing from Amundi provides a snapshot of its investment strategy but may not represent its current holdings.
Related Filing Alerts
Source: Amundi's 13F filing on $CME (May 18, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Amundi 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts